1854061-19-0 Usage
Uses
Used in Pharmaceutical Industry:
(S)-2-hydroxy-2-(2-(2-methoxy-5-methylpyridin-3-yl)ethyl)-succinic acid is used as a SLC13A family inhibitor for its potential therapeutic applications. As a compound with structural similarities to citrate, it can modulate the activity of the Na+-citrate cotransporter (NaCT), which is involved in various physiological processes. By inhibiting the SLC13A family of solute channels, (S)-2-hydroxy-2-(2-(2-methoxy-5-methylpyridin-3-yl)ethyl)-succinic acid may have implications in the treatment of conditions related to the dysregulation of these transporters.
Used in Drug Development:
In the field of drug development, (S)-2-hydroxy-2-(2-(2-methoxy-5-methylpyridin-3-yl)ethyl)-succinic acid can be utilized to determine its unbound partition coefficient (Kpuu) in rats. This parameter is crucial for understanding the compound's pharmacokinetics and its potential for oral absorption. Additionally, its potency as a drug can be estimated, providing valuable information for further research and development into its therapeutic potential.
Used in Chemical Synthesis:
Due to its unique structure, (S)-2-hydroxy-2-(2-(2-methoxy-5-methylpyridin-3-yl)ethyl)-succinic acid can serve as a building block or intermediate in the synthesis of more complex molecules. It may be used in the development of novel pharmaceuticals, agrochemicals, or other specialty chemicals that require its specific functional groups and stereochemistry.
Biochem/physiol Actions
PF-06761281 is an inhibitor of the sodium-coupled citrate transporter (NaCT or SLC13A5), which may be a target for tretment and prevention of metabolic disorders. The SLC13 transporters SLC13A2 (NaDC1), SLC13A3 (NaDC3), and SLC13A5 (NaCT) co-transport di- and tricarboxylates with multiple sodium ions into cells. PF-06761281 inhibits citrate uptake with an IC50 of 740 nM for NaCT in human hepatocytes. PF-06761281 has >25-fold in vitro selectivity for NaCT over NaDC1 and NaDC3 and was inactive in a selectivity panel of 65 targets.
Check Digit Verification of cas no
The CAS Registry Mumber 1854061-19-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,5,4,0,6 and 1 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1854061-19:
(9*1)+(8*8)+(7*5)+(6*4)+(5*0)+(4*6)+(3*1)+(2*1)+(1*9)=170
170 % 10 = 0
So 1854061-19-0 is a valid CAS Registry Number.
1854061-19-0Relevant articles and documents
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family
Huard, Kim,Gosset, James R.,Montgomery, Justin I.,Gilbert, Adam,Hayward, Matthew M.,Magee, Thomas V.,Cabral, Shawn,Uccello, Daniel P.,Bahnck, Kevin,Brown, Janice,Purkal, Julie,Gorgoglione, Matthew,Lanba, Adhiraj,Futatsugi, Kentaro,Herr, Michael,Genung, Nathan E.,Aspnes, Gary,Polivkova, Jana,Garcia-Irizarry, Carmen N.,Li, Qifang,Canterbury, Daniel,Niosi, Mark,Vera, Nicholas B.,Li, Zhenhong,Khunte, Bhagyashree,Siderewicz, Jaclyn,Rolph, Timothy,Erion, Derek M.
, p. 1165 - 1175 (2016)
Inhibition of the sodium-coupled citrate transporter (NaCT or SLC13A5) has been proposed as a new therapeutic approach for prevention and treatment of metabolic diseases. In a previous report, we discovered dicarboxylate 1a (PF-06649298) which inhibits th